News Belite Bio, Inc

Equities

BLTE

US07782B1044

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
48.5 ^USD	-0.86%		-2.92%	+6.01%

12/06	Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan	MT
12/06	Belite Bio, Inc. Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Belite Bio Receives Sakigake Designation of Tinlarebant for Stargardt Disease in Japan	13/06	AQ
Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan	12/06	MT
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	12/06	GL
Belite Bio, Inc. Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	12/06	CI
Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024	15/05
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference	14/05	GL
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference	14/05	AQ
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Belite Bio's Q1 Loss Narrows	14/05	MT
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update	14/05	GL
Transcript : Belite Bio, Inc - Special Call	13/05
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05	GL
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05	AQ
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results	08/05	GL
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant	06/05	GL
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	06/05	GL
Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	06/05	CI
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting	02/05	GL
Belite Bio Unveils Plan to Offer 651,380 American Depository Shares	26/04	MT
Belite Bio Announces $25 Million Registered Direct Offering	26/04	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Belite Bio, Inc

Equities

BLTE

US07782B1044

Summary

Filters